<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-02-05</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-02-05 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">105</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-02-06 04:14</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-30">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/30</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-31">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/31</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-02-01">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">02/01</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-02">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">02/02</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-03">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">02/03</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-04">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">02/04</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-05">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">02/05</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šå‘ˆç°å¤šç»´åº¦æ´»è·ƒæ€åŠ¿ï¼ŒAIé©±åŠ¨çš„æ–°è¯ç ”å‘å…¬å¸Generate:Biomedicinesåœ¨å¯åŠ¨å…³é”®IIIæœŸè¯•éªŒåè¿…é€Ÿç”³è¯·IPOï¼Œå‡¸æ˜¾äº†èµ„æœ¬å¸‚åœºå¯¹AIåˆ¶è¯çš„é«˜åº¦å…³æ³¨ã€‚åŒæ—¶ï¼Œå›´ç»•GLP-1è¯ç‰©ï¼ˆå¦‚è¯ºå’Œè¯ºå¾·çš„Wegovyï¼‰çš„å¸‚åœºç«äº‰åŠ å‰§ï¼ŒHims & Hersæ¨å‡ºä½ä»·å¤æ–¹ç‰ˆæœ¬å¼•å‘æ³•å¾‹ä¸ç›‘ç®¡äº‰è®®ï¼Œè€Œç¤¼æ¥å’Œè¯ºå’Œè¯ºå¾·å‡­å€Ÿå¼ºåŠ²é”€å”®æ•°æ®ç»§ç»­ä¸»å¯¼è¯¥é¢†åŸŸã€‚æ­¤å¤–ï¼Œç¾å›½æ”¿åºœçš„èµ„é‡‘æ³•æ¡ˆé‡æ–°æˆæƒäº†ç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’ï¼Œä¸ºç›¸å…³è¯ç‰©å¼€å‘æä¾›äº†æ”¿ç­–æ¿€åŠ±ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>1. Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: æ–°è¯ç ”å‘<br>
   - AIåˆ¶è¯é¢†å†›ä¼ä¸šåœ¨å…³é”®IIIæœŸè¯•éªŒå¯åŠ¨åç«‹å³ç”³è¯·IPOï¼Œæ ‡å¿—ç€AIé©±åŠ¨è¯ç‰©ç ”å‘è¿›å…¥èµ„æœ¬åŒ–å…³é”®é˜¶æ®µï¼Œå¯¹è¡Œä¸šå…·æœ‰é£å‘æ ‡æ„ä¹‰ã€‚</p>
<p><strong>10. Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - GLP-1è¯ç‰©å¸‚åœºç«äº‰ç™½çƒ­åŒ–ï¼Œä½ä»·å¤æ–¹ç‰ˆæœ¬çš„å‡ºç°å¯èƒ½é¢ è¦†å®šä»·æ¨¡å¼ï¼Œå¼•å‘å“ç‰Œè¯ä¼æ³•å¾‹åå‡»ä¸FDAç›‘ç®¡å…³æ³¨ï¼Œå½±å“å·¨å¤§ã€‚</p>
<p><strong>2. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - ç¾å›½æ”¿åºœèµ„é‡‘æ³•æ¡ˆé‡æ–°æˆæƒç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’è‡³2029å¹´ï¼Œä¸ºç›¸å…³è¯ç‰©ç ”å‘æä¾›äº†æŒç»­çš„æ”¿ç­–æ¿€åŠ±ï¼Œå½±å“ç ”å‘å¯¼å‘ã€‚</p>
<p><strong>14. Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026</strong> â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - ç¤¼æ¥å…¬å¸GLP-1è¯ç‰©Mounjaroå’ŒZepboundé”€å”®åŠ¿å¤´å¼ºåŠ²ï¼Œ2025å¹´åˆè®¡é”€å”®é¢è¶…360äº¿ç¾å…ƒï¼Œå…¶2026å¹´ä¹è§‚é¢„æµ‹å·©å›ºäº†å…¶åœ¨ä»£è°¢ç–¾ç—…é¢†åŸŸçš„é¢†å¯¼åœ°ä½ã€‚</p>
<p><strong>17. Amgen resists FDA request to pull rare disease drug Tavneos from the market</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - å®‰è¿›å…¬å¸ç½•è§ç—…è¯ç‰©Tavneosé¢ä¸´FDAæ’¤å¸‚è¦æ±‚ä½†äºˆä»¥æ‹’ç»ï¼Œå‡¸æ˜¾äº†è¯å“ä¸Šå¸‚åç›‘ç®¡ä¸è¯ä¼ä¹‹é—´çš„æ½œåœ¨å†²çªï¼Œå¯¹ç½•è§ç—…è¯ç‰©å¸‚åœºæœ‰è­¦ç¤ºä½œç”¨ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): ä»¥Generate:Biomedicinesä¸ºä»£è¡¨çš„AIé©±åŠ¨è¯ç‰©å‘ç°å…¬å¸æˆä¸ºç„¦ç‚¹ï¼Œå…¶IPOç”³è¯·ä¸ç ”å‘è¿›å±•åŒæ­¥ï¼Œæ˜¾ç¤ºæŠ€æœ¯å¹³å°æ­£åŠ é€Ÿå‘ä¸´åºŠå’Œèµ„æœ¬å¸‚åœºè½¬åŒ–ã€‚æ­¤å¤–ï¼ŒVeradermicsé’ˆå¯¹ç”Ÿå‘ç­‰ç¾å­¦é¢†åŸŸçš„å£æœè¯ç‰©ç ”å‘ä¹Ÿè·å¾—èµ„æœ¬é’çã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): æ–°é—»ä¸­ç›´æ¥æåŠçš„ä¸´åºŠè¯•éªŒè¿›å±•è¾ƒå°‘ï¼Œä½†Generate:Biomedicinesåœ¨é¦–ä¸ªæ‚£è€…ç»™è¯9å¤©åå³ç”³è¯·IPOï¼Œæš—ç¤ºå…¶IIIæœŸè¯•éªŒçš„å¯åŠ¨æ˜¯å…³é”®çš„å‚¬åŒ–å‰‚ã€‚BMSä¹Ÿé¢„å‘Šäº†å¤šé¡¹å³å°†åˆ°æ¥çš„åæœŸç®¡çº¿æ•°æ®è¯»å‡ºï¼Œå¯èƒ½å¸¦æ¥æ–°çš„å‚¬åŒ–å‰‚ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>éœ€å¯†åˆ‡å…³æ³¨FDAå¯¹Hims & Hersé”€å”®å¤æ–¹GLP-1è¯ç‰©å¯èƒ½é‡‡å–çš„ç›‘ç®¡è¡ŒåŠ¨ï¼Œä»¥åŠè¯ºå’Œè¯ºå¾·æ˜¯å¦ä¼šæ­£å¼å¯åŠ¨æ³•å¾‹è¯‰è®¼ã€‚åŒæ—¶ï¼ŒGenerate:Biomedicinesç­‰å¤šå®¶ç”Ÿç‰©æŠ€æœ¯å…¬å¸çš„IPOå®šä»·å’Œé¦–æ—¥è¡¨ç°å°†åæ˜ èµ„æœ¬å¸‚åœºå¯¹ç”Ÿç‰©ç§‘æŠ€æ¿å—ï¼Œç‰¹åˆ«æ˜¯AIåˆ¶è¯é¢†åŸŸçš„æƒ…ç»ªã€‚æ­¤å¤–ï¼Œå°åº¦æ”¿åºœå®£å¸ƒçš„11äº¿ç¾å…ƒç”Ÿç‰©åˆ¶å‰‚/ç”Ÿç‰©ç±»ä¼¼è¯æŠ•èµ„è®¡åˆ’çš„å…·ä½“å®æ–½ç»†èŠ‚å€¼å¾—å…³æ³¨ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Flagship&#39;s Generate:Biomedicines files for IPO, pitching AI-driven drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 12:00</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO. The Flagship Pioneering-backed startup has become a richly-funded leader of AI bio since its founding in ...</p>
                    
                    <a href="https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon IPO analysis: Big biotech names, big valuation cut
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:32</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">For Eikon Therapeutics, its IPO feels more like something itâ€™s surviving rather than celebrating. The Bay Area startup is one of biotechâ€™s most prominent privately-held companies, after raising more than $1 billion to advance its ...</p>
                    
                    <a href="https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rare pediatric PRV program reauthorized until 2029 via government funding law
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 18:27</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">President Donald Trump on Tuesday signed the government funding extension that also reauthorized the FDA&#39;s ability to issue rare pediatric priority reviews through 2029, reviving an incentive program that industry has fought to keep. ...</p>
                    
                    <a href="https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:22</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Thermo Fisher Scientific is closing its chemical analysis manufacturing site in Franklin, MA, due to â€œcurrent customer demands,â€ a company spokesperson told Endpoints News. Operations there will be phased out by the end of the ...</p>
                    
                    <a href="https://endpoints.news/thermo-fisher-charles-river-workforce-cuts-wuxi-signs-contract-with-vertex/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab, SpyGlass bank a combined $350M in biotech IPOs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-06 00:59</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The two offerings capped off the busiest week for new biotech stock issuances in a year.</p>
                    
                    <a href="https://www.biopharmadive.com/news/agomab-spyglass-biotech-ipo-price-2026/811385/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo, Lilly sputter as Hims launches knockoff GLP-1 pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 17:22</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo is threatening litigation in response to the move by the telehealth company to &amp;ldquo;unlawfully mass-market&amp;rdquo; what it called an &amp;ldquo;unapproved, inauthentic, and untested knockoff&amp;rdquo; of its fast-selling medication.</p>
                    
                    <a href="https://www.biopharmadive.com/news/hims-compounded-wegovy-glp-1-obesity-novo-lilly/811476/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generate, an AI-driven Flagship startup, pitches an IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 16:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.</p>
                    
                    <a href="https://www.biopharmadive.com/news/generate-biomedicines-ipo-flagship-ai-tlsp/811482/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 01:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.</p>
                    
                    <a href="https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 17:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly soars again as fast-selling weight loss drugs top Wall Street projections
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 16:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Despite some angst over pricing pressure for GLP-1 drugs, Lilly&amp;rsquo;s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.</p>
                    
                    <a href="https://www.biopharmadive.com/news/lilly-earnings-guidance-q4-2025-obesity-drugs/811317/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA chief Makary takes aim at Hims&#39; compounded Wegovy pill plans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 23:52</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Commissioner Marty Makary took a not-so-subtle swipe at Hims &amp;amp; Hers in a social media post Thursday, saying his agency would &#34;take swift action against companies mass-marketing illegal copycat drugs.&#34; Without naming Hims, Makary&#39; ...</p>
                    
                    <a href="https://endpoints.news/fda-chief-makary-takes-aim-at-hims-compounded-wegovy-pill-plans/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Veradermics CEO has a great hair day with 122% pop in IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 18:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Investors are showing some love to the biotech testing an oral form of Rogaine, betting that people will want good hair too as the aesthetics market surges with direct-to-consumer GLP-1s. Veradermics&#39; stock surged 122% in ...</p>
                    
                    <a href="https://endpoints.news/veradermics-ceo-has-a-great-hair-day-with-122-pop-in-ipo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers draws pipeline excitement as several data readouts near
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:50</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">For the first time in a while, investors seem excited about Bristol Myers Squibbâ€™s late-stage pipeline. Bristol Myers on Thursday flagged at least 10 potential data readouts coming this year that could lead to new ...</p>
                    
                    <a href="https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Telehealth provider Hims goes after Novo&#39;s weight loss pill with compounded version
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:58</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Online healthcare provider Hims &amp;amp; Hers said it would start selling a compounded version of Novo Nordiskâ€™s Wegovy pill on Thursday, just a month after the FDAâ€™s approval of the brand-name pill version of the ...</p>
                    
                    <a href="https://endpoints.news/telehealth-provider-hims-goes-after-novos-weight-loss-pill-with-compounded-version/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eisai gains Henlius therapy; LB Pharma snags $100M in funding
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/eisai-gains-henlius-therapy-lb-pharma-snags-100m-in-funding/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Veradermics lands $256M IPO for oral Rogaine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Veradermics headed out of the gates with an initial public offering that garnered $256 million in gross proceeds, a bigger-than-expected debut that suggests investors may be hungry for a rebound in biotech listings. Veradermics, which ...</p>
                    
                    <a href="https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hims adds Grail&#39;s cancer test amid questions about widespread use
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Hims &amp;amp; Hers is bringing Grail&#39;s cancer test to its consumer health platform, marking a significant step toward mass adoption of a technology that&#39;s shown progress while remaining under scientific debate. Grail, a pioneer in ...</p>
                    
                    <a href="https://endpoints.news/hims-adds-grails-cancer-test-amid-questions-about-widespread-use/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novartis says generics to erode $4B from 2026 sales
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 12:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis said further generic erosion of three blockbuster medicines, including its top-selling heart failure drug Entresto, will leave a $4 billion hole in its sales this year. Generic competition started to make a mark in ...</p>
                    
                    <a href="https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA seeks withdrawal of Amgen&#39;s Tavneos, but company says it won&#39;t pull drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 00:48</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Several years of questions about Amgen&#39;s rare disease treatment Tavneos have reached a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans to ...</p>
                    
                    <a href="https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayer details anticipated stroke prevention data for new blood-thinner
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 17:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Asundexian&amp;nbsp;cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.</p>
                    
                    <a href="https://www.biopharmadive.com/news/bayer-asundexian-factorXIa-secondary-stroke-data-conference/811455/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #ISC26: Bayerâ€™s asundexian reduced ischemic strokes by 26% in Phase 3 trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 17:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...</p>
                    
                    <a href="https://endpoints.news/isc26-bayers-asundexian-reduced-ischemic-strokes-by-26-in-phase-3-trial/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Angitia gets $130M Series D for pipeline of musculoskeletal drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 12:30</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short. Angitia Biopharmaceuticals disclosed its Series D ...</p>
                    
                    <a href="https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myersâ€™ waiting game
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 21:32</span>
                        
                    </div>
                    
                    <p class="news-summary">Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.</p>
                    
                    <a href="https://www.biopharmadive.com/news/bristol-myers-abbvie-gsk-vaccines-biotech-earnings-q4-2025/811463/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Express Scripts reaches â€˜landmarkâ€™ settlement with FTC in insulin suit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 11:46</span>
                        
                    </div>
                    
                    <p class="news-summary">The agreement announced Wednesday includes sweeping changes to the Cigna PBM&amp;rsquo;s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.</p>
                    
                    <a href="https://www.biopharmadive.com/news/express-scripts-ftc-reach-settlement-insulin-lawsuit/811436/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo shares tumble by double digits on grim sales outlook
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 16:55</span>
                        
                    </div>
                    
                    <p class="news-summary">In contrast to Lilly&amp;rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s threat to sue Hims over Wegovy pill faces legal hurdle
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 21:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk&#39;s threatened legal action against Hims &amp;amp; Hers for selling a compounded version of the pharma giantâ€™s newly launched Wegovy pill may be far from a slam-dunk win. Dae Lee, an attorney at Buchanan ...</p>
                    
                    <a href="https://endpoints.news/novos-threat-to-sue-hims-over-wegovy-pill-faces-legal-hurdle/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        White House launches TrumpRx
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 20:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The White House on Thursday launched TrumpRx, the long-awaited direct-to-consumer hub that&#39;s a cornerstone of the administrationâ€™s push to lower drug prices. The official unveiling had been months in the making and was slightly delayed ...</p>
                    
                    <a href="https://endpoints.news/white-house-plans-to-launch-trumprx-thursday/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GLP-1s and the Super Bowl
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:41</span>
                        
                    </div>
                    
                    <p class="news-summary">The Super Bowl is once again getting the GLP-1 ad treatment. Hims &amp;amp; Hers is back with another combative spot that calls out the disparities in healthcare experiences between the ...</p>
                    
                    <a href="https://endpoints.news/glp-1s-and-the-super-bowl/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FTC settles insulin lawsuit with Express Scripts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 20:49</span>
                        
                    </div>
                    
                    <p class="news-summary">The FTC has settled with Express Scripts over its use of insulin rebates, securing an agreement that stretches across almost every corner of the company&#39;s business model. The commission and Express Scripts</p>
                    
                    <a href="https://endpoints.news/ftc-settles-insulin-lawsuit-with-express-scripts/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie says immunology blockbusters will be &#39;main drivers&#39; of growth post-Humira
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 20:40</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/abbvie-says-immunology-blockbusters-will-be-main-drivers-of-growth-post-humira/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSKâ€™s new CEO eyes more dealmaking, intense pipeline inspection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 15:01</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK CEO Luke Miels laid out the drugmakerâ€™s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir. â€œWe need ...</p>
                    
                    <a href="https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Midi Health raises $100M as it plans expansion into urgent care, research
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Health techâ€™s latest unicorn is Midi Health, a womenâ€™s health startup launched during the pandemic that has since expanded into broader virtual care with a recent focus on longevity. The startup hit ...</p>
                    
                    <a href="https://endpoints.news/midi-health-raises-100m-as-it-plans-expansion-into-urgent-care-research/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 12:10</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly surpassed analysts&#39; expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects ...</p>
                    
                    <a href="https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 10:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer&#39;s monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has ...</p>
                    
                    <a href="https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">43 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 15:02</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rising Stars: emagineHealth&#39;s Barbara Leal lives and works by the mantra of â€˜humans first, professionals secondâ€™
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 15:25</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In a Q&amp;amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Leal explained how healthcare and pharma marketing combines the â€œbest of both worldsâ€ for her.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Him &amp;amp; Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 12:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims &amp;amp; Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.</p>
                    
                    <a href="https://www.fiercepharma.com/health-tech/him-hers-plans-offer-cheaper-version-wegovy-pill-prompting-novo-nordisk-threaten-legal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 11:16</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The majority of Bristol Myers Squibb&#39;s $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/stagnating-sales-older-legacy-meds-bms-leans-new-growth-drivers-weather-storm" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Astellas tops expectations as Vyloy sales surge outshines trial setback
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 10:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astellas-tops-expectations-vyloy-sales-surge-outshines-trial-setback" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A cut above: Veradermics locks in $256M IPO and shares spike
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 09:43</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according to a Securities and Exchange Commission filing. Veradermics is trading under the symbol &#34;MANE.&#34;</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/cut-above-hair-regrowth-biotech-veradermics-locks-oversubscribed-256m-ipo" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company&#39;s momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;amp;J competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie&#39;s immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company&#39;s yearly haul of $61.1 billion.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        As CEO, Luke Miels wants GSK to be more &#39;product-centric&#39;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Amgen resists FDA request to pull rare disease drug Tavneos from the market
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 07:41</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/amgen-resists-fda-request-pull-rare-disease-drug-tavneos-market-0" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        India will invest $1.1B to boost development of biologics, biosimilars
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 14:25</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Based on ads released in advance of the Super Bowl, little has changed in the eyes of the pharma industry since the FDA began a &#34;crackdown&#34; on drug marketing</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/05/fda-ftc-pbm-super-bowl-teva-autism-layoffs-vertex-amgen/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On Super Bowl Sunday, the drug industry is trotting out lounging football stars, a shouting DJ Khaled, and the soothing tones of Enya.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/drug-ads-super-bowl-sunday-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BMS celebrates US soccer legend&#39;s shutout against cancer in Breyanzi collab
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 11:20</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:47</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        TrumpRx, US government&#39;s cash-pay drug purchasing portal, primed for launch
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 14:31</span>
                        
                    </div>
                    
                    <p class="news-summary">On Thursday evening, President Donald Trump is set to debut TrumpRx, a government-run website that will direct patients toward cash-pay channels where they can purchase certain prescription drugs.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumprx-governments-cash-pay-drug-purchasing-tool-primed-launch" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 07:41</span>
                        
                    </div>
                    
                    <p class="news-summary">Merz Therapeutics has launched a punchy marketing campaign for Parkinsonâ€™s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the medâ€™s â€œFor the Fightersâ€ initiative.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/merz-steps-ring-muhammad-ali-inbrija-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharma marks Super Bowl â€˜SUNdayâ€™ with skin cancer awareness drive
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">For Sun Pharma, every dayâ€”from Super Bowl Sunday and beyondâ€”is â€œSUNday.â€</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/sun-pharma-marks-super-bowl-sunday-skin-cancer-awareness-drive" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 13:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: Novo shares plummet on sales, profit warning for &#39;26 as 2 top execs head for the door
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 13:39</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sweden&#39;s Nanologica acquires API facility from CDMO Ardena, brings team of 45 on board
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 08:31</span>
                        
                    </div>
                    
                    <p class="news-summary">Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardenaâ€™s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/swedens-nanologica-acquires-ardenas-syntagon-facility-stock-trade-deal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A &#39;game of inches&#39;: Pfizer channels Al Pacino in World Cancer Day ad
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/pfizer-channels-al-pacino-spirited-world-cancer-day-ad" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS launches $100M antiviral prize to develop broad-spectrum therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:39</span>
                        
                    </div>
                    
                    <p class="news-summary">While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Charles River to close cell therapy CDMO site, lay off 20 staffers
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.</p>
                    
                    <a href="https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As top-selling Keytruda inches closer to its 2028 patent cliff, Merck&#39;s confidence in sustainable growth for the future is &#34;as high as it&#39;s ever been,&#34; CEO Robert Davis said on the company&#39;s full-year 2025 earnings call.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Statins donâ€™t cause most of the side effects on package warnings, study finds
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 23:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Many people who should be taking statins avoid them for fear of side effects. A large new study says most of those side effects don&#39;t actually show up.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/statin-side-effects-evidence-lacking-lancet-study-says/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk accuses Hims &amp; Hers of â€˜illegal mass compoundingâ€™ over a cheaper version of Wegovy pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 20:51</span>
                        
                    </div>
                    
                    <p class="news-summary">Hims &amp;#38; Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of â€œillegal&amp;#8230;</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What to know about TrumpRx, the Trump administrationâ€™s prescription drug platform
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 18:00</span>
                        
                    </div>
                    
                    <p class="news-summary">On Thursday, President Trump launched TrumpRx, the website he and his aides have touted for months as a platform aimed at lowering prescription drug prices.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/trumprx-what-to-know-drug-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo and Lilly both see price cuts as helpful for long-term gain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/biotech-news-novo-and-lilly-price-cuts-for-gain/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Opinion: TrumpRx has a fundamental flaw
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The real winners from TrumpRx are pharmaceutical manufacturers.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/trumprx-prescription-drug-costs-flaws/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Vertexâ€™s CRISPR treatment for sickle cell disease hits unexpected roadblock
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Vertex is running out of time to establish Casgevy as a transformative treatment for sickle cell.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/vertex-crispr-sickle-cell-treatment-casgevy-faces-rollout-bottleneck/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 18:07</span>
                        
                    </div>
                    
                    <p class="news-summary">The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer defends data on Metsera candidate
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:44</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 17:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer unveils data on Metsera drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:41</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer moves forward with its hopes for a monthly obesity drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: A play takes on Novoâ€™s myth and money
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:51</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oncology (Cancer)/Hematologic Malignancies Approval Notifications
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:46</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA does not&amp;nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&amp;nbsp;Drugs@FDA&amp;nbsp;for the latest approvals and prescribing information for specific products.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        List of Determinations Including Written Request
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:49</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/list-determinations-including-written-request" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cefiderocol Injection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Cefiderocol Injection - FDA Identified Interpretive Criteria</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/cefiderocol-injection" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Notices of Updates
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:04</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Webpage providing notices of updates to FDA&#39;s STIC webpages for antibacterial and antifungal drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/notices-updates" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Newly Added Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Guidance documents represent the FDA&#39;s current thinking on a particular subject. New guidance documents are listed here for three months.</p>
                    
                    <a href="http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rare Disease Drug Approvals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:38</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This page describes recent rare disease drug approvals that received a CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.</p>
                    
                    <a href="http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Office of Infectious Diseases Research Activities
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:35</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Overview of research needs, requests for information (RFIs), public workshops/meetings, opportunities for collaboration (this applies to RFI), notable guidances related to regulatory science, externally awarded research studies, and other important regulatory science and research activities.</p>
                    
                    <a href="http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-infectious-diseases-research-activities" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Search for Regulatory References | Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 00:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Find information on drug development, applications, submissions, manufacturing &amp;amp; quality, safety, labeling and more</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/search-regulatory-references-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 21:13</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Recently Issued Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:30</span>
                        
                    </div>
                    
                    <p class="news-summary">This page lists Recently Issued CBER and Cross-Center Guidance Documents.</p>
                    
                    <a href="http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        National Drug Code Directory
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:59</span>
                        
                    </div>
                    
                    <p class="news-summary">National Drug Code Directory</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Electronic Registration and Listing Compliance Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:59</span>
                        
                    </div>
                    
                    <p class="news-summary">Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).</p>
                    
                    <a href="http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:28</span>
                        
                    </div>
                    
                    <p class="news-summary">INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS</p>
                    
                    <a href="http://www.fda.gov/news-events/expanded-access/informed-consent-template-individual-patient-expanded-access" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Antibacterial Susceptibility Test Interpretive Criteria
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Antibacterial Susceptibility Test Interpretive Criteria</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        E22 General Considerations for Patient Preference Studies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:54</span>
                        
                    </div>
                    
                    <p class="news-summary">E22 General Considerations for Patient Preference Studies</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e22-general-considerations-patient-preference-studies" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rare Disease News, Events &amp; Reports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Learn more about recent news and events related to rare diseases and read ARC Program Annual Reports.</p>
                    
                    <a href="http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-news-events-reports" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:38</span>
                        
                    </div>
                    
                    <p class="news-summary">As part of the Accelerating Rare disease Cures (ARC) Program, CDERâ€™s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.</p>
                    
                    <a href="http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/learning-and-education-advance-and-empower-rare-disease-drug-developers-leader-3d" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rare Diseases Team
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:38</span>
                        
                    </div>
                    
                    <p class="news-summary">The Rare Diseases Program facilitates, supports and accelerates the development of drug and biologic products for the benefit of patients with rare disorders</p>
                    
                    <a href="http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-diseases-team" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:18</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The US sees around 476,000 new Lyme cases every year</p>
                    
                    <a href="https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient-centric oncology trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-05 11:35</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Data-driven, patient-first: using insights in striving to transform cancer care</p>
                    
                    <a href="https://pharmatimes.com/thought_leadership/patient-centric-oncology-trials/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IBSA UK&amp;I launches Perovial for the treatment of acute Peyronieâ€™s disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease</p>
                    
                    <a href="https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Connect more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-05 11:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Redefining the future of customer relationships in biopharma</p>
                    
                    <a href="https://pharmatimes.com/thought_leadership/connect-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thomas Farrell
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:48</span>
                        
                    </div>
                    
                    <p class="news-summary">NanoSyrinx has appointed Thomas Farrell as CEO and Director</p>
                    
                    <a href="https://pharmatimes.com/appointments/thomas-farrell/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ahmed Moussa
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Ahmed Moussa is the new Sanofi Country Lead for UK &amp;#038; Ireland</p>
                    
                    <a href="https://pharmatimes.com/appointments/ahmed-moussa/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:43</span>
                        
                    </div>
                    
                    <p class="news-summary">The company will initially develop a vaccine to tackle colorectal and pancreatic cancers</p>
                    
                    <a href="https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys</p>
                    
                    <a href="https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-02-06 04:14</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>